Andre M.
- Country
- Portugal
- Department
- Oncology
Research Overview
- Evaluation of [Main Substance] in Combination with Other Agents for Patients with Metastatic Clear Cell or Papillary Renal Cell Carcinoma and End-Stage Renal Disease
- Phase I Study of BAY2927088 in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR and/or HER2 Mutations
- Phase 1 Evaluation of NDI-219216 in Advanced Solid Tumors with/without Microsatellite Instability and Deficient Mismatch Repair
Data & Insights
Has run more than one trial at 45 of 169 partner sites.
Specializations
Thoracic Oncology
The investigator specializes in treating non-small cell lung cancer (NSCLC), with particular focus on cases involving EGFR and HER2 genetic mutations. Their research extends to both early-stage and advanced disease states.
- Advanced NSCLC management
- Post-surgical adjuvant therapy
- Targeted molecular treatments
Genitourinary Oncology
Expertise in treating complex urological cancers, including metastatic castration-resistant prostate cancer, muscle invasive bladder cancer, and renal cell carcinoma.
- Advanced bladder cancer therapies
- Prostate cancer treatment
- Kidney cancer management
Rare and Endocrine Tumors
Focus on rare oncological conditions including pheochromocytoma, paraganglioma, and pancreatic neuroendocrine tumors. Additional expertise in von Hippel-Lindau disease-associated tumors.
- Neuroendocrine tumor treatment
- Genetic tumor syndromes
- HIF-2α related malignancies
Breast Oncology
Specialization in hormone receptor-positive breast cancer, particularly ER+/HER2- early breast cancer, with emphasis on extended endocrine therapeutic approaches.
- Hormone receptor-positive disease
- Extended adjuvant therapy
- Endocrine resistance management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.